Peripheral neuropathy associated with mitochondrial disease in children

Developmental Medicine and Child Neurology

Volumn 54, Issue 5, 2012, Pages 407-414

  Menezes, Manoj P ^a   Ouvrier, Robert A ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; NUCLEAR PROTEIN;

ARTICLE; CLINICAL ASSESSMENT; DEMYELINATING NEUROPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENE MUTATION; GIANT AXONAL NEUROPATHY; HISTOPATHOLOGY; HUMAN; LEIGH DISEASE; LIVER BIOPSY; MITOCHONDRIAL DNA DISORDER; MUSCLE BIOPSY; NEUROPHYSIOLOGY; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN BIOPSY;

CHILD; DNA MUTATIONAL ANALYSIS; DNA-DIRECTED DNA POLYMERASE; EARLY DIAGNOSIS; GENETIC TESTING; HUMANS; LEIGH DISEASE; MEMBRANE PROTEINS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; OPTIC NERVE DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; PHENOTYPE; SECONDARY PREVENTION;

EID: 84859500654     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2012.04271.x     Document Type: Article

References (95)

1. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010; 9: 829-40.
2. Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. Biochim Biophys Acta 2010; 1797: 113-28.
3. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905-12.
4. Funalot B. Peripheral neuropathies due to mitochondrial disorders. Rev Neurol (Paris) 2009; 165: 1118-21.
5. Finsterer J. Inherited mitochondrial neuropathies. J Neurol Sci 2011; 304: 9-16.
6. Colomer J, Iturriaga C, Bestue M, et al. Aspects of neuropathy in mitochondrial diseases. Rev Neurol 2000; 30: 1117-21.
7. Isohanni P, Hakonen AH, Euro L, et al. POLG1 manifestations in childhood. Neurology 2011; 76: 811-15.
8. Darin N, Oldfors A, Moslemi A-R, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol 2001; 49: 377-83.
9. Ferrari G, Lamantea E, Donati A, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 2005; 128: 723-31.
10. Hakonen AH, Isohanni P, Paetau A, Herva R, Suomalainen A, Lönnqvist T. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain 2007; 130: 3032-40.
11. Sarzi E, Goffart S, Serre V, et al. Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. Ann Neurol 2007; 62: 579-87.
12. Lönnqvist T, Paetau A, Nikali K, von Boguslawski K, Pihko H. Infantile onset spinocerebellar ataxia with sensory neuropathy (IOSCA): neuropathological features. J Neurol Sci 1998; 161: 57-65.
13. Koskinen T, Sainio K, Rapola J, Pihko H, Paetau A. Sensory neuropathy in infantile onset spinocerebellar ataxia (IOSCA). Muscle Nerve 1994; 17: 509-15.
14. Lönnqvist T, Paetau A, Valanne L, Pihko H. Recessive twinkle mutations cause severe epileptic encephalopathy. Brain 2009; 132: 1553-62.
15. Dimmock DP, Zhang Q, Dionisi-Vici C, et al. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mutat 2008; 29: 330-1.
16. Appenzeller O, Kornfeld M, Snyder R. Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children. Arch Neurol 1976; 33: 733-8.
17. Karadimas CL, Vu TH, Holve SA, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet 2006; 79: 544-8.
18. Spinazzola A, Santer R, Akman OH, et al. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. Arch Neurol 2008; 65: 1108-13.
19. Ostergaard E. Disorders caused by deficiency of succinate-CoA ligase. J Inherit Metab Dis 2008; 31: 226-9.
20. Carrozzo R, Dionisi-Vici C, Steuerwald U, et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 2007; 130: 862-74.
21. Morava E, Steuerwald U, Carrozzo R, et al. Dystonia and deafness due to SUCLA2 defect; Clinical course and biochemical markers in 16 children. Mitochondrion 2009; 9: 438-42.
22. den Boer MEJ, Dionisi-Vici C, Chakrapani A, van Thuijl AOJ, Wanders RJA, Wijburg FA. Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr 2003; 142: 684-9.
23. Spiekerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29: 66-72.
24. Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008; 39: 223-35.
25. Barkovich AJ. An approach to MRI of metabolic disorders in children. J Neuroradiol 2007; 34: 75-88.
26. Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion 2008; 8: 396-413.
27. Thorburn DR, Rahman S. Mitochondrial DNA-associated Leigh syndrome and NARP. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews. Seattle, WA, USA: University of Washington, 2003: (updated 2011).
28. Bruno C, Biancheri R, Garavaglia B, et al. A novel mutation in the SURF1 gene in a child with Leigh Disease, peripheral neuropathy, and cytochrome-c oxidase deficiency. J Child Neurol 2002; 17: 233-6.
29. Santoro L, Carrozzo R, Malandrini A, et al. A novel SURF1 mutation results in Leigh syndrome with peripheral neuropathy caused by cytochrome c oxidase deficiency. Neuromuscul Disord 2000; 10: 450-3.
30. Fujii T, Hattori H, Higuchi Y, Tsuji M, Mitsuyoshi I. Phenotypic differences between T→C and T→G mutations at nt 8993 of mitochondrial DNA in Leigh syndrome. Pediatr Neurol 1998; 18: 275-7.
31. Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
32. Rojo A, Campos Y, Sánchez J, et al. NARP-MILS syndrome caused by 8993T>G mitochondrial DNA mutation: a clinical, genetic and neuropathological study. Acta Neuropathol (Berl) 2006; 111: 610-16.
33. Castagna AE, Addis J, McInnes RR, et al. Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9, 185 of mitochondrial DNA. Am J Med Genet A 2007; 143A: 808-16.
34. Craig K, Elliott HR, Keers SM, et al. Episodic ataxia and hemiplegia caused by the 8993T->C mitochondrial DNA mutation. J Med Genet 2007; 44: 797-9.
35. de Vries DD, van Engelen BG, Gabreels FJ, Ruitenbeek W, van Oost BA. A second missense mutation in the mitochondrial ATPase 6 gene in Leigh's syndrome. Ann Neurol 1993; 34: 410-12.
36. van Erven PM, Gabreels FJ, Ruitenbeek W, Renier WO, Lamers KJ, Sloof JL. Familial Leigh's syndrome: association with a defect in oxidative metabolism probably restricted to brain. J Neurol 1987; 234: 215-19.
37. Childs AM, Hutchin T, Pysden K, et al. Variable phenotype including Leigh syndrome with a 9185T>C mutation in the MTATP6 gene. Neuropediatrics 2007; 38: 313-6.
38. Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012; 105: 34-43.
39. Di Rocco M, Doria Lamba L, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. Eur J Paediatr Neurol 2000; 4: 115-7.
40. Bonne G, Benelli C, De Meirleir L, et al. E1 pyruvate dehydrogenase deficiency in a child with motor neuropathy. Pediatr Res 1993; 33: 284-8.
41. Chabrol B, Mancini J, Benelli C, Gire C, Munnich A. Leigh syndrome: pyruvate dehydrogenase defect. A case with peripheral neuropathy. J Child Neurol 1994; 9: 52-5.
42. Federico A, Dotti MT, Fabrizi GM, et al. Congenital lactic acidosis due to a defect of pyruvate dehydrogenase complex (E1). Clinical, biochemical, nerve biopsy study and effect of therapy. Eur Neurol 1990; 30: 123-7.
43. Marsac C, Benelli C, Desguerre I, et al. Biochemical and genetic studies of four patients with pyruvate dehydrogenase E1 alpha deficiency. Hum Genet 1997; 99: 785-92.
44. Sedel F, Challe G, Mayer JM, et al. Thiamine responsive pyruvate dehydrogenase deficiency in an adult with peripheral neuropathy and optic neuropathy. J Neurol Neurosurg Psychiatry 2008; 79: 846-7.
45. Stickler DE, Carney PR, Valenstein ER. Juvenile-onset Leigh syndrome with an acute polyneuropathy at presentation. J Child Neurol 2003; 18: 574-6.
46. Miyake N, Yamashita S, Kurosawa K, et al. A novel homozygous mutation of DARS2 may cause a severe LBSL variant. Clin Genet 2011; 80: 293-6.
47. Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007; 39: 534-9.
48. Isohanni P, Linnankivi T, Buzkova J, et al. DARS2 mutations in mitochondrial leucoencephalopathy and multiple sclerosis. J Med Genet 2010; 47: 66-70.
49. Távora DGF, Nakayama M, Gama RL, Alvim TC, Portugal D, Comerlato EA. Leukoencephalopathy with brainstem and spinal cord involvement and high brain lactate: report of three Brazilian patients. Arq Neuropsiquiatr 2007; 65: 506-11.
50. McLaughlin HM, Sakaguchi R, Liu C, et al. Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet 2010; 87: 560-6.
51. Eymard B, Penicaud A, Leger JM, et al. Clinical and electrophysiologic study of the peripheral nerve in 28 cases of mitochondrial disease. Rev Neurol (Paris) 1991; 147: 508-12. (In French).
52. Zanssen S, Molnar M, Buse G, Schroder JM. Mitochondrial cytochrome b gene deletion in Kearns-Sayre syndrome associated with a subclinical type of peripheral neuropathy. Clin Neuropathol 1998; 17: 291-6.
53. McDonald DG, McMenamin JB, Farrell MA, Droogan O, Green AJ. Familial childhood onset neuropathy and cirrhosis with the 4977bp mitochondrial DNA deletion. Am J Med Genet 2002; 111: 191-4.
54. Molnar M, Neudecker S, Schroder JM. Increase of mitochondria in vasa nervorum of cases with mitochondrial myopathy, Kearns-Sayre syndrome, progressive external ophthalmoplegia and MELAS. Neuropathol Appl Neurobiol 1995; 21: 432-9.
55. Schroder JM. Neuropathy associated with mitochondrial disorders. Brain Pathol 1993; 3: 177-90.
56. Kärppä M, Syrjälä P, Tolonen U, Majamaa K. Peripheral neuropathy in patients with the 3243A>G mutation in mitochondrial DNA. J Neurol 2003; 250: 216-21.
57. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66: 324-30.
58. Stickler DE, Valenstein E, Neiberger RE, et al. Peripheral neuropathy in genetic mitochondrial diseases. Pediatr Neurol 2006; 34: 127-31.
59. Bouillot S, Martin-Negrier ML, Vital A, et al. Peripheral neuropathy associated with mitochondrial disorders: 8 cases and review of the literature. J Peripher Nerv Syst 2002; 7: 213-20.
60. Erol I, Alehan F, Horvath R, Schneiderat P, Talim B. Demyelinating disease of central and peripheral nervous systems associated with a A8344G mutation in tRNALys. Neuromuscul Disord 2009; 19: 275-8.
61. Wong LJ, Naviaux RK, Brunetti-Pierri N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008; 29: E150-72.
62. Longley MJ, Nguyen D, Kunkel TA, Copeland WC. The fidelity of human DNA polymerase γ with and without exonucleolytic proofreading and the p55 accessory subunit. J Biol Chem 2001; 276: 38555-62.
63. Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006; 129: 1685-92.
64. Van Goethem G, Martin JJ, Dermaut B, et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003; 13: 133-42.
65. Van Goethem G, Mercelis R, Lofgren A, et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology 2003; 61: 1811-3.
66. Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase g gene. Brain 2006; 129: 1674-84.
67. Stewart JD, Tennant S, Powell H, et al. Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children. J Med Genet 2009; 46: 209-14.
68. Hirano M, Garcia-de-Yebenes J, Jones AC, et al. Mitochondrial neurogastrointestinal encephalomyopathy syndrome maps to chromosome 22q13.32-qter. Am J Hum Genet 1998; 63: 526-33.
69. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in mngie, a human mitochondrial disorder. Science 1999; 283: 689-92.
70. Papadimitriou A, Comi G, Hadjigeorgiou G, et al. Partial depletion and multiple deletions of muscle mtDNA in familial MNGIE syndrome. Neurology 1998; 51: 1086-92.
71. Hirano M, Nishigaki Y, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist 2004; 10: 8-17.
72. Shaibani A, Shchelochkov OA, Zhang S, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol 2009; 66: 1028-32.
73. Bedlack RS, Vu T, Hammans S, et al. MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2004; 29: 364-8.
74. Simon LT, Horoupian DS, Dorfman LJ, et al. Polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudo-obstruction: POLIP syndrome. Ann Neurol 1990; 28: 349-60.
75. Perez-Atayde AR, Fox V, Teitelbaum JE, et al. Mitochondrial neurogastrointestinal encephalomyopathy: diagnosis by rectal biopsy. Am J Surg Pathol 1998; 22: 1141-7.
76. Hirano M, Marti R, Casali C, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006; 67: 1458-60.
77. Halter J, Schupbach WMM, Casali C, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 2011; 46: 330-7.
78. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet 2009; 46: 145-58.
79. Gilhuis HJ, Schelhaas HJ, Cruysberg JRM, Zwarts MJ. Demyelinating polyneuropathy in Leber hereditary optic neuropathy. Neuromuscul Disord 2006; 16: 394-5.
80. Nikoskelainen EK, Marttila RJ, Huoponen K, et al. Leber's "plus": neurological abnormalities in patients with Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 1995; 59: 160-4.
81. Alexander C, Votruba M, Pesch UEA, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26: 211-15.
82. Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133: 771-86.
83. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol 2009; 256: 9-17.
84. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 2009; 256(Suppl. 1): 3-8.
85. Ouvrier RA, McLeod JG, Conchin TE. Friedreich's ataxia: early detection and progression of peripheral nerve abnormalities. J Neurol Sci 1982; 55: 137-45.
86. Santoro L, De Michele G, Perretti A, et al. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J Neurol Neurosurg Psychiatry 1999; 66: 93-6.
87. Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell 2009; 20: 3525-32.
88. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160: 189-200.
89. Züchner S, Mersiyanova IV, Muglia M. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-51.
90. Züchner S, Jonghe PD, Jordanova A, et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 2006; 59: 276-81.
91. Vallat J-M, Ouvrier RA, Pollard JD, et al. Histopathological findings in hereditary motor and sensory neuropathy of axonal type with onset in early childhood associated with mitofusin 2 mutations. J Neuropathol Exp Neurol 2008; 67: 1097-102.
92. Nelis E, Erdem S, Van Den Bergh PY, et al. Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy. Neurology 2002; 59: 1865-72.
93. Claramunt R, Pedrola L, Sevilla T, et al. Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J Med Genet 2005; 42: 358-65.
94. Cassereau J, Chevrollier A, Gueguen N, et al. Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K). Neurogenetics 2009; 10: 145-50.
95. Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 2005; 170: 1067-78.